Latest Strategy Changes News

Multistack International Limited posted a surprising $2.26 million net profit for 2025, driven by one-off settlement income, while its core operations continue to falter, prompting plans to exit its current business model.

WA Kaolin reported $2.7 million in sales for the December quarter, secured a $1.5 million working capital loan, and restructured $20.4 million of debt, while focusing on plant improvements and cost reductions to address negative margins.

BSA Limited reported an 84% plunge in revenue for the half-year ending December 2025, driven by lost contracts and reduced volumes, yet managed a $6.3 million profit amid restructuring and cost controls. Significant board changes signal a strategic reset as the company navigates uncertain waters.

Advanced Innergy Holdings Ltd (ASX:AIH) has reported a robust FY25 performance highlighted by a successful IPO and strong growth across its core segments, setting a confident tone for FY26.

Rural Funds Group has reported a striking 292% surge in profit after tax for the half year ending December 2025, alongside a 13% rise in revenue, signalling robust growth in its agricultural property portfolio.

SRJ Technologies has secured multiple new purchase orders for its BoltEx flange clamp technology from major international operators, reinforcing its growing global footprint and industry validation.

Cobram Estate Olives reported a widened half-year loss driven by higher oil costs and operating expenses, while progressing its US growth strategy with a major California acquisition.

Energy Resources of Australia reported a significantly reduced net loss of $50 million for 2025, driven by rehabilitation provision adjustments and higher interest income. Meanwhile, rehabilitation delays and Rio Tinto’s compulsory acquisition efforts highlight ongoing operational and ownership challenges.

PeopleIN reported half-year earnings in line with expectations while strategically acquiring New Zealand’s Infrawork to bolster its infrastructure recruitment footprint across the Asia Pacific.

Telix Pharmaceuticals delivered a strong 56% revenue increase in 2025, driven by U.S. sales of Illuccix and the launch of Gozellix, while advancing its therapeutic pipeline and expanding global manufacturing capabilities. Despite a net loss, the company is investing heavily in R&D and sustainability initiatives aligned with climate-related disclosures.

MyState Limited reported a robust half-year result with a 61% rise in underlying net profit, driven by the full impact of its Auswide Bank merger and strong growth across key business lines. The company also declared a fully franked interim dividend of 12 cents per share.

AdAlta Limited reported a $2.44 million loss for H1 FY26 while progressing a key CAR-T therapy collaboration and raising $2.8 million in capital. The company’s ‘East to West’ immunotherapy strategy gains momentum with regulatory tailwinds and cost efficiencies.